Skip to main content
OpenTrials
Completed

NCT Number: NCT01680068

Air Tamponade in Macular Hole Surgery

Macular hole is a hole formation which takes place in the center of the retina. Such a hole needs surgical steps in order to close. Closure of the macular hole will lead to a substantially improvement of vision in most cases. Following macular hole surgery a tamponade of intraocular gas is normally injected in order to keep the macula dry for the postoperative period. Postoperative face down position for a week was earlier standard. Several authors report of good closure rates with both air tamponade or lack of face down positioning. In this study standard pars plana vitrectomy with peeling of the internal limiting membrane (ILM) will be performed. The gas tamponade will be replaced by air. Postoperative face down positioning will not be used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Macular Hole Eye Diseases Retinal Diseases Retinal Perforations

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stavanger University Hospital, Department of Ophthalmology

Stavanger, 4016, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Idiopathic stage 2 - 4 macular hole
  • Duration of symptoms ≤ 36 months
  • Informed consent

Exclusion criteria

  • Previous vitreomacular surgery
  • Myopia ≥ 6 diopters
  • Ocular trauma
  • Disease affecting visual function

Treatment and study plan

Pars plana vitrectomy and postoperative air tamponade

Procedure

Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.

Primary outcomes

  1. Closure rate of macular hole

    Time frame: 1 month after enrollment

Secondary outcomes

  1. Closure rate in macular holes larger than 400 micrometer

    Time frame: 1 month after enrollment

Other outcomes

  1. Visual gain after 6 months of follow up

    Time frame: 6 months after enrollment

Sponsors and collaborators

Lead sponsor

Helse Stavanger HF

Other Gov

Collaborators

  • Haukeland University Hospital

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 6, 2012
Registry last updated
Dec 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.